Kronos Bio Inc
NASDAQ:KRON

Watchlist Manager
Kronos Bio Inc Logo
Kronos Bio Inc
NASDAQ:KRON
Watchlist
Price: 0.88 USD 1.49% Market Closed
Market Cap: 53.7m USD

Net Margin
Kronos Bio Inc

-701.5%
Current
-1 843%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-701.5%
=
Net Income
-64.5m
/
Revenue
9.2m

Net Margin Across Competitors

No Stocks Found

Kronos Bio Inc
Glance View

Market Cap
53.7m USD
Industry
Biotechnology

Kronos Bio, Inc. is a clinical-stage biopharmaceutical, engages in the provision of discovery and development of novel cancer therapeutics products. The company is headquartered in San Mateo, California and currently employs 96 full-time employees. The company went IPO on 2020-10-09. The firm is focused on the discovery and development of cancer therapeutics designed to target dysregulated transcription. Its product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) that drive their oncogenic activity. Its lead product candidate, entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase (SYK) inhibitor that is being developed for the treatment of acute myeloid leukemia (AML). Its second product candidate, KB-0742, is generated from its product engine’s small molecule microarray (SMM) platform. KB-0742 is designed to be an orally bioavailable inhibitor of CDK9 with a differentiated selectivity profile. Its KB-0742 is in advanced solid tumors with MYC genomic copy number gain (amplification).

KRON Intrinsic Value
1.59 USD
Undervaluation 45%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-701.5%
=
Net Income
-64.5m
/
Revenue
9.2m
What is the Net Margin of Kronos Bio Inc?

Based on Kronos Bio Inc's most recent financial statements, the company has Net Margin of -701.5%.

Back to Top